Evidence map›Paper›PMID 36192617›Full record

Trial reportJournal of assisted reproduction and genetics2022

Hormone concentrations of dominant follicles in the TALES randomized controlled trial comparing letrozole with tamoxifen.

Ange Wang, Joseph M Letourneau, Flor Juarez-Hernandez, Mary Kathryn Abel, Evelyn Mok-Lin, Mitchell P Rosen

Open access · greenAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of assisted reproduction and genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ange WangDivision of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street 6th Floor, San Francisco, CA, 94158, USA. ange.wang@ucsf.edu.ORCID http://orcid.org/0000-0002-7133-0950
Joseph M LetourneauUniversity of Utah, Salt Lake City, UT, USA.
Flor Juarez-HernandezDivision of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street 6th Floor, San Francisco, CA, 94158, USA.
Mary Kathryn AbelDivision of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street 6th Floor, San Francisco, CA, 94158, USA.
Evelyn Mok-LinDivision of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street 6th Floor, San Francisco, CA, 94158, USA.
Mitchell P RosenDivision of Reproductive Endocrinology and Infertility, University of California, San Francisco, 499 Illinois Street 6th Floor, San Francisco, CA, 94158, USA.
University of California, San Francisco · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn this secondary analysis of the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) trial, we aimed to investigate if concurrent administration of letrozole vs. tamoxifen vs. no added treatment affects hormonal composition and size of stimulated ovarian follicles.

methodsTALES is a randomized controlled trial of IVF stimulation for estrogen receptor (ER)-positive breast cancer patients stimulated with gonadotropins and administered concurrent tamoxifen 20 mg or letrozole 5 mg. We analyzed estradiol (E2), testosterone (T), progesterone (P4), follicle stimulating hormone (FSH), luteinizing hormone (LH), and anti-Mullerian hormone (AMH). We used ANOVA/Kruskal-Wallis, logistic, and linear regression models to examine differences in follicular hormone levels, size, and mature oocyte yield between trial arm.

resultsWe included data from total 246 follicles (94 letrozole, 82 tamoxifen, and 70 control) from 123 unique participants. E2 was lower (letrozole 187.4, tamoxifen 1026.0, control 821.5 ng/mL, p < 0.01) and T was higher (letrozole 2489, tamoxifen 571, and control 504 ng/mL, p < 0.03) in the letrozole group compared to tamoxifen and control groups, while other hormone levels and follicle size were similar across groups. There were no significant differences in hormone concentrations within the follicle between tamoxifen and control arms. On multivariate logistic regression, there was no significant association of mature oocyte yield by follicle size, hormone levels, or trial arm.

conclusionsConcurrent administration of letrozole with gonadotropins affects follicular E2 and T concentrations compared to tamoxifen/control. Tamoxifen was not associated with any differences in hormone concentrations within the follicle. Mature oocyte yield was similar across groups.

Indexed as

Follicle Stimulating HormoneTamoxifenEstradiolFemaleGonadotropinsHumansLetrozoleOvarian FollicleEstradiolFollicle Stimulating HormoneGonadotropinsLetrozoleTamoxifenEstradiolFertility preservationFollicular fluidLetrozoleTamoxifenTestosterone

Identifiers

PMID36192617
PMCPMC9723077
OpenAlexW4300816655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.